418 related articles for article (PubMed ID: 19183105)
1. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.
Tannergren C; Bergendal A; Lennernäs H; Abrahamsson B
Mol Pharm; 2009; 6(1):60-73. PubMed ID: 19183105
[TBL] [Abstract][Full Text] [Related]
2. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
Dahan A; Amidon GL
Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
[TBL] [Abstract][Full Text] [Related]
3. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
4. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
[TBL] [Abstract][Full Text] [Related]
5. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
Varma MV; Sateesh K; Panchagnula R
Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
[TBL] [Abstract][Full Text] [Related]
6. Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs.
Rozehnal V; Nakai D; Hoepner U; Fischer T; Kamiyama E; Takahashi M; Yasuda S; Mueller J
Eur J Pharm Sci; 2012 Aug; 46(5):367-73. PubMed ID: 22418036
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of an in vitro faecal degradation method for early assessment of the impact of colonic degradation on colonic absorption in humans.
Tannergren C; Borde A; Boreström C; Abrahamsson B; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():200-6. PubMed ID: 24514453
[TBL] [Abstract][Full Text] [Related]
8. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
Cao X; Yu LX; Barbaciru C; Landowski CP; Shin HC; Gibbs S; Miller HA; Amidon GL; Sun D
Mol Pharm; 2005; 2(4):329-40. PubMed ID: 16053336
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique.
Sjöberg Å; Lutz M; Tannergren C; Wingolf C; Borde A; Ungell AL
Eur J Pharm Sci; 2013 Jan; 48(1-2):166-80. PubMed ID: 23103351
[TBL] [Abstract][Full Text] [Related]
10. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Tsume Y; Amidon GL
Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
[TBL] [Abstract][Full Text] [Related]
11. The use of drug metabolism for prediction of intestinal permeability (dagger).
Chen ML; Yu L
Mol Pharm; 2009; 6(1):74-81. PubMed ID: 19132929
[TBL] [Abstract][Full Text] [Related]
12. Investigation of regional mechanisms responsible for poor oral absorption in humans of a modified release preparation of the alpha-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): the rational use of ex vivo intestine to predict in vivo absorption.
Collett A; Stephens RH; Harwood MD; Humphrey M; Dallman L; Bennett J; Davis J; Carlson GL; Warhurst G
Drug Metab Dispos; 2008 Jan; 36(1):87-94. PubMed ID: 17932223
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
14. Prediction of human pharmacokinetics--gastrointestinal absorption.
Fagerholm U
J Pharm Pharmacol; 2007 Jul; 59(7):905-16. PubMed ID: 17637184
[TBL] [Abstract][Full Text] [Related]
15. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests.
Kim JS; Mitchell S; Kijek P; Tsume Y; Hilfinger J; Amidon GL
Mol Pharm; 2006; 3(6):686-94. PubMed ID: 17140256
[TBL] [Abstract][Full Text] [Related]
16. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
Sharma P; Varma MV; Chawla HP; Panchagnula R
Farmaco; 2005; 60(11-12):874-83. PubMed ID: 16243320
[TBL] [Abstract][Full Text] [Related]
17. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
Mishra V; Gupta U; Jain NK
Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
[TBL] [Abstract][Full Text] [Related]
18. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs.
Fossati L; Dechaume R; Hardillier E; Chevillon D; Prevost C; Bolze S; Maubon N
Int J Pharm; 2008 Aug; 360(1-2):148-55. PubMed ID: 18539418
[TBL] [Abstract][Full Text] [Related]
19. Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay.
Thiel-Demby VE; Humphreys JE; St John Williams LA; Ellens HM; Shah N; Ayrton AD; Polli JW
Mol Pharm; 2009; 6(1):11-8. PubMed ID: 19248229
[TBL] [Abstract][Full Text] [Related]
20. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
